%0 Journal Article
%T Estado actual de la vacuna recombinante contra el virus del papiloma humano
%A Chan Ac¨®n
%A Wendy
%A Aguilar Morales
%A Lara
%A Soley
%A Carolina
%A Arguedas Mohs
%A Adriano
%J Acta Pedi¨¢trica Costarricense
%D 2008
%I Scientific Electronic Library Online
%X genital human papillomavirus (hpv) is one of the most common sexually transmitted infections worldwide. millions of persons are now infected and the lifetime risk of hpv infection exceeds 50%. hpv is approximately 100% related to the total cases of cervical cancer, 100% of cervical intraepithelial neoplasias grade 1, 2, and 3; 40% of vulva, vagina and penile cancer, 100% of genital warts, 100% of recurrent respiratory papillomatosis and 12% of head and neck cancer. licensed vaccines, gardasil£¿ and cervarix£¿, are composed of a noninfectious mixture of hpv type-specific virus-like particles prepared from the l1 proteins produced by recombinant dna technology and adsorbed in a aluminum-containing adjuvant. data from several studies of both vaccines reported a range of efficacy of 98,9 % to 100.0% for the prevention of cervical, vulvar and vaginal intraepithelial neoplasias degrees 2 and 3, and therefore, cervical, vulvar and vaginal cancer related to the vph-16/18; in addition to in situ adenocarcinomas and genital warts caused by vph-16/18/6/11. the effectiveness for both vaccines is maintained for at least 5 years. at the moment no therapeutic effect has been attributed and the vaccine use is prophylactic, nevertheless, vaccination should not be considered as a substitute for cervical cancer screening.
%K genital human papillomavirus
%K hpv
%K recombinant vaccine
%K gardasil
%K cervarix.
%U http://www.scielo.sa.cr/scielo.php?script=sci_abstract&pid=S1409-00902008000200007&lng=en&nrm=iso&tlng=en